Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25811310 | 0.88 | RAD52 (0.59) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL25814907 | 0.77 | KDM4E (0.44) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL25812105 | 0.76 | KDM4E (0.43) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL2161458 | 0.74 | KMT2A (0.62) | MAPTKDM4EKMT2AALDH1A1MAPK1 | |
| SCHEMBL2161575 | 0.73 | HTR3A (0.65) | MAPTKMT2AMEN1CACNA1GHTR3A | |
| SCHEMBL25300551 | 0.70 | KMT2A (0.76) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL25811381 | 0.70 | KMT2A (0.78) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL2161450 | 0.69 | KMT2A (0.68) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL30401813 | 0.68 | RAD52 (0.74) | MAPTKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL25811302 | 0.68 | RAD52 (0.74) | MAPTKDM4EHSD17B10KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | MAPT 18/4885KDM4E 1465/4885HSD17B10 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.